whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial

Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the pu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of dairy science 2011-02, Vol.94 (2), p.589-601
Hauptverfasser: Berthold, H.K, Schulte, D.M, Lapointe, J.F, Lemieux, P, Krone, W, Gouni-Berthold, I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 601
container_issue 2
container_start_page 589
container_title Journal of dairy science
container_volume 94
creator Berthold, H.K
Schulte, D.M
Lapointe, J.F
Lemieux, P
Krone, W
Gouni-Berthold, I
description Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.
doi_str_mv 10.3168/jds.2010-3115
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_847282862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>847282862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</originalsourceid><addsrcrecordid>eNpFkU1v1DAQhi0EotvCkSv4gjil-CMfDreqgoJUiQP0HE2cSdcrJ15sR-3yf_ifTNgFTuN59eidGb-MvZLiUsvavN8N6VIJKQotZfWEbWSlKnq35inbCKFUIbRQZ-w8pR21UonqOTujWjVCmQ379bDFAx8xTjhnyC7MfB_DsNjMJ_Aeofe4KhndTEqO7pEPaCNCwsSpvfcHi9ENyG2YLZnEPy6JE5-Wfoc2J_7g8pZvD3uMdhs8poyRyuTgA7_iEeYhTO4nDnzvwWIfCrLKRHiSaAT4F-zZCD7hy1O9YHefPn6__lzcfr35cn11W1htqlzUiKZUqkULSqG2CGOtwVrZj4PoVWPKAexY0_6maSojjJRlOyL2DTS6MbW-YO-OvnTxj4X27CaXLHoPM4YldaZslFGmVkQWR9LGkFLEsdtHN0E8dFJ0azAdBdOtwXRrMMS_Pjkv_YTDP_pvEgS8PQGQLPiRfsW69J_TNLcVq9GbIzdC6OA-EnP3jeaUQoi2rKXWvwE3L6Xx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>847282862</pqid></control><display><type>article</type><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</creator><creatorcontrib>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</creatorcontrib><description>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</description><identifier>ISSN: 0022-0302</identifier><identifier>EISSN: 1525-3198</identifier><identifier>DOI: 10.3168/jds.2010-3115</identifier><identifier>PMID: 21257028</identifier><identifier>CODEN: JDSCAE</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>animal models ; Animal productions ; Anticholesteremic Agents - therapeutic use ; Biological and medical sciences ; blood glucose ; blood lipids ; blood pressure ; body mass index ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Cultured Milk Products ; Double-Blind Method ; Female ; fermentation ; Food industries ; Fundamental and applied biological sciences. Psychology ; glycohemoglobin ; high density lipoprotein cholesterol ; Humans ; hypercholesterolemia ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; lactic acid bacteria ; lipid content ; low density lipoprotein ; Male ; Middle Aged ; Milk and cheese industries. Ice creams ; Milk Proteins - therapeutic use ; Risk Factors ; Terrestrial animal productions ; Treatment Outcome ; Triglycerides - blood ; Vertebrates ; whey ; Whey Proteins</subject><ispartof>Journal of dairy science, 2011-02, Vol.94 (2), p.589-601</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</citedby><cites>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23828905$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21257028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berthold, H.K</creatorcontrib><creatorcontrib>Schulte, D.M</creatorcontrib><creatorcontrib>Lapointe, J.F</creatorcontrib><creatorcontrib>Lemieux, P</creatorcontrib><creatorcontrib>Krone, W</creatorcontrib><creatorcontrib>Gouni-Berthold, I</creatorcontrib><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><title>Journal of dairy science</title><addtitle>J Dairy Sci</addtitle><description>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</description><subject>animal models</subject><subject>Animal productions</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>blood lipids</subject><subject>blood pressure</subject><subject>body mass index</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Cultured Milk Products</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>fermentation</subject><subject>Food industries</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>glycohemoglobin</subject><subject>high density lipoprotein cholesterol</subject><subject>Humans</subject><subject>hypercholesterolemia</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>lactic acid bacteria</subject><subject>lipid content</subject><subject>low density lipoprotein</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Milk and cheese industries. Ice creams</subject><subject>Milk Proteins - therapeutic use</subject><subject>Risk Factors</subject><subject>Terrestrial animal productions</subject><subject>Treatment Outcome</subject><subject>Triglycerides - blood</subject><subject>Vertebrates</subject><subject>whey</subject><subject>Whey Proteins</subject><issn>0022-0302</issn><issn>1525-3198</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1v1DAQhi0EotvCkSv4gjil-CMfDreqgoJUiQP0HE2cSdcrJ15sR-3yf_ifTNgFTuN59eidGb-MvZLiUsvavN8N6VIJKQotZfWEbWSlKnq35inbCKFUIbRQZ-w8pR21UonqOTujWjVCmQ379bDFAx8xTjhnyC7MfB_DsNjMJ_Aeofe4KhndTEqO7pEPaCNCwsSpvfcHi9ENyG2YLZnEPy6JE5-Wfoc2J_7g8pZvD3uMdhs8poyRyuTgA7_iEeYhTO4nDnzvwWIfCrLKRHiSaAT4F-zZCD7hy1O9YHefPn6__lzcfr35cn11W1htqlzUiKZUqkULSqG2CGOtwVrZj4PoVWPKAexY0_6maSojjJRlOyL2DTS6MbW-YO-OvnTxj4X27CaXLHoPM4YldaZslFGmVkQWR9LGkFLEsdtHN0E8dFJ0azAdBdOtwXRrMMS_Pjkv_YTDP_pvEgS8PQGQLPiRfsW69J_TNLcVq9GbIzdC6OA-EnP3jeaUQoi2rKXWvwE3L6Xx</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Berthold, H.K</creator><creator>Schulte, D.M</creator><creator>Lapointe, J.F</creator><creator>Lemieux, P</creator><creator>Krone, W</creator><creator>Gouni-Berthold, I</creator><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><author>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>animal models</topic><topic>Animal productions</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>blood lipids</topic><topic>blood pressure</topic><topic>body mass index</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Cultured Milk Products</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>fermentation</topic><topic>Food industries</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>glycohemoglobin</topic><topic>high density lipoprotein cholesterol</topic><topic>Humans</topic><topic>hypercholesterolemia</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>lactic acid bacteria</topic><topic>lipid content</topic><topic>low density lipoprotein</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Milk and cheese industries. Ice creams</topic><topic>Milk Proteins - therapeutic use</topic><topic>Risk Factors</topic><topic>Terrestrial animal productions</topic><topic>Treatment Outcome</topic><topic>Triglycerides - blood</topic><topic>Vertebrates</topic><topic>whey</topic><topic>Whey Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berthold, H.K</creatorcontrib><creatorcontrib>Schulte, D.M</creatorcontrib><creatorcontrib>Lapointe, J.F</creatorcontrib><creatorcontrib>Lemieux, P</creatorcontrib><creatorcontrib>Krone, W</creatorcontrib><creatorcontrib>Gouni-Berthold, I</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dairy science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berthold, H.K</au><au>Schulte, D.M</au><au>Lapointe, J.F</au><au>Lemieux, P</au><au>Krone, W</au><au>Gouni-Berthold, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</atitle><jtitle>Journal of dairy science</jtitle><addtitle>J Dairy Sci</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>94</volume><issue>2</issue><spage>589</spage><epage>601</epage><pages>589-601</pages><issn>0022-0302</issn><eissn>1525-3198</eissn><coden>JDSCAE</coden><abstract>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>21257028</pmid><doi>10.3168/jds.2010-3115</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-0302
ispartof Journal of dairy science, 2011-02, Vol.94 (2), p.589-601
issn 0022-0302
1525-3198
language eng
recordid cdi_proquest_miscellaneous_847282862
source MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects animal models
Animal productions
Anticholesteremic Agents - therapeutic use
Biological and medical sciences
blood glucose
blood lipids
blood pressure
body mass index
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cultured Milk Products
Double-Blind Method
Female
fermentation
Food industries
Fundamental and applied biological sciences. Psychology
glycohemoglobin
high density lipoprotein cholesterol
Humans
hypercholesterolemia
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
lactic acid bacteria
lipid content
low density lipoprotein
Male
Middle Aged
Milk and cheese industries. Ice creams
Milk Proteins - therapeutic use
Risk Factors
Terrestrial animal productions
Treatment Outcome
Triglycerides - blood
Vertebrates
whey
Whey Proteins
title whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A03%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=whey%20fermentation%20product%20malleable%20protein%20matrix%20decreases%20triglyceride%20concentrations%20in%20subjects%20with%20hypercholesterolemia:%20A%20randomized%20placebo-controlled%20trial&rft.jtitle=Journal%20of%20dairy%20science&rft.au=Berthold,%20H.K&rft.date=2011-02-01&rft.volume=94&rft.issue=2&rft.spage=589&rft.epage=601&rft.pages=589-601&rft.issn=0022-0302&rft.eissn=1525-3198&rft.coden=JDSCAE&rft_id=info:doi/10.3168/jds.2010-3115&rft_dat=%3Cproquest_cross%3E847282862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=847282862&rft_id=info:pmid/21257028&rfr_iscdi=true